Melanoma patients in a phase I clinic: Molecular aberrations, targeted therapy and outcomes

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2158-2165

  Henary, H ^a   Hong, D S ^a   Falchook, G S ^a   Tsimberidou, A ^a   George, G C ^a   Wen, S ^a   Wheler, J ^a   Fu, S ^a   Naing, A ^a   Piha Paul, S ^a   Janku, F ^a   Kim, K B ^a   Hwu, P ^a   Kurzrock, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Matched therapy; Melanoma; Metastatic melanoma; Phase I; Targeted therapy

Indexed keywords

B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAF GENE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GNAQ GENE; HUMAN; HUMAN TISSUE; KIT GENE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MUTATOR GENE; NRAS GENE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

MATCHED THERAPY; MELANOMA; METASTATIC MELANOMA; PHASE I; TARGETED THERAPY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GTP PHOSPHOHYDROLASES; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; RAS PROTEINS; SURVIVAL; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84881221698     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt115     Document Type: Article

References (42)

1. Wheler J, Tsimberidou AM, Hong D, et al. Survival of 1181 patients in a phase I clinic: the MD Anderson clinical center for targeted therapy experience. Clin Cancer Res 2012; 18: 2922-2929.
2. Miller AJ, Mihm MC, Jr. Melanoma. N Engl J Med 2006; 355: 51-65.
3. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687-701.
4. Cohen MH, Johnson JR, Middleton MR. Temozolomide for advanced, metastatic melanoma. J Clin Oncol 2000; 18: 2185.
5. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6(Suppl 1): S11-S14.
6. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer 2004; 40: 1825-1836.
7. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
8. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1581-1588.
9. Lens M, Ferrucci PF, Testori A. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov 2008; 3: 105-113.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
11. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebocontrolled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598.
12. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26: 5950-5956.
13. Wallander ML, Layfield LJ, Emerson LL, et al. KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol 2011; 24: 1031-1035.
14. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
15. Akslen LA, Puntervoll H, Bachmann IM, et al. Mutation analysis of the EGFRNRAS- BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 2008; 18: 29-35.
16. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005; 115: 813-824.
17. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
18. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
19. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-1901.
20. Smalley KS, Flaherty KT. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer 2009; 100: 431-435.
21. von Euw E, Atefi M, Attar N, et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 2012; 11: 22.
22. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-599.
23. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
24. Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 2005; 352: 930-932.
25. Arkenau HT, Olmos D, Ang JE, et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008; 98: 1029-1033.
26. Garrido-Laguna I, Janku F, Vaklavas C, et al. Validation of the Royal MarsdenHospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer 2012; 118: 1422-1428.
27. Jain RK, Lee JJ, Hong D, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010; 16: 1289-1297.
28. Roberts TG, Jr, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004; 292: 2130-2140.
29. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352: 895-904.
30. El-Osta H, Falchook G, Tsimberidou A, et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 2011; 6: e25806.
31. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-782.
32. Ambrosini G, Pratilas CA, Qin L-X, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res 2012; 18: 1-10.
33. Zuo Z, Chen SS, Chandra PK, et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 2009; 22: 1023-1031.
34. Margraf RL, Durtschi JD, Dames S, et al. Multi-sample pooling and illumina genome analyzer sequencing methods to determine gene sequence variation for database development. J Biomol Tech 2010; 21: 126-140.
35. Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 2006; 24: 2987-2990.
36. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. Lancet Oncol 2012; 13: 773-781.
37. Falchook GS, Lewis KD, Infante JrR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 782-789.
38. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49: 5230-5234.
39. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602.
40. Nishino M, Jagannathan JP, Ramaiya NH, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 2010; 195: W221-W228.
41. Nishino M, Jackman DM, Hatabu H, et al. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010; 195: 281-289.
42. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A: 1135-1141.